---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-026375"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T15:27:28.889701+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech acquires collagen assets for $15.25M; funds with $12M loan from Cadence Bank

## Summary
- Acquired IP, manufacturing rights, and four 510(k)-cleared products including CellerateRX and HYCOL.
- Purchase price: $9.75M cash, $3.0M in stock (73,809 shares), $2.5M in four annual installments.
- Entered $12M term loan with Cadence Bank at Term SOFR + 3%, maturing August 2028.
- Sellers eligible for up to $10M earnout based on future sales of a collagen product under development.

## SEC filing metadata
- accession: 0001493152-23-026375
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/0001493152-23-026375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-026375
- JSON: https://secwatch.observer/filing/0001493152-23-026375.json
- Plain text: https://secwatch.observer/filing/0001493152-23-026375.txt

## Key facts
- M&A Transactions
  Sanara MedTech Inc. completed an acquisition involving The Hymed Group Corporation and Applied Nutritionals, LLC for $15.25 million (closed 2023-08-01).
  - Action: acquisition
  - Counterparty: The Hymed Group Corporation and Applied Nutritionals, LLC
  - Consideration: $15.25 million
  - Closing: 2023-08-01
  source text: HYCOL Hydrolyzed Collagen (Powder and Gel) (“HYCOL”) products for human wound care use. The Purchased Assets were purchased for an initial aggregate purchase price of $15.25 million, consisting of (i) $9.75 million in cash (the “Cash Closing Consideration”), (ii) 73,809 shares of the Company’s common stock, par value $0.001 per share (the “Stock Closing
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/0001493152-23-026375-index.htm
- Material Agreements
  Sanara MedTech Inc. entered into Asset Purchase Agreement with The Hymed Group Corporation, Applied Nutritionals, LLC, and Dr. George D. Petito valued at initial aggregate purchase price of $15.25 million (effective 2023-08-01).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: The Hymed Group Corporation, Applied Nutritionals, LLC, and Dr. George D. Petito
  - Value: initial aggregate purchase price of $15.25 million
  - Effective: 2023-08-01
  source text: On August 1, 2023, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company, as guarantor, Sanara MedTech Applied Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (the “Purchaser”), The Hymed Group Corporation, a Delaware corporation (“Hymed”), Applied Nutritionals, LLC, a Delaware limited liability company (“Applied” and, together with Hymed, the “Sellers”), and Dr. George D. Petito (the “Owner”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/0001493152-23-026375-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.